Authors: Beurton, I Bertrand, MA Bresson-Hadni, S Parquet-Gernez, A Goudemand, J Paris, JC Cales, P Briquel, ME Gaucher, P Cortey, ML Trepo, C Miguet, JP Cahn, JY

Citation: I. Beurton et al., Interferon alpha therapy in haemophilic patients with chronic hepatitis C:a French multicentre pilot study of 58 patients, EUR J GASTR, 13(7), 2001, pp. 859-864

Authors: Christophe, OD Lenting, PJ Cherel, G Boon-Spijker, M Lavergne, JM Boertjes, R Briquel, ME de Goede-Bolder, A Goudemand, J Gaillard, S d'Oiron, R Meyer, D Mertens, K

Citation: Od. Christophe et al., Functional mapping of anti-factor IX inhibitors developed in patients withsevere hemophilia B, BLOOD, 98(5), 2001, pp. 1416-1423

Authors: Ulsemer, P Lanza, F Baas, MJ Schwartz, A Ravanat, C Briquel, ME Cranmer, S Jackson, S Cazenave, JP de la Salle, C

Citation: P. Ulsemer et al., Role of the leucine-rich domain of platelet GPIb alpha in correct post-translational processing - The Nancy I Bernard-Soulier mutation expressed on CHO cells, THROMB HAEM, 84(1), 2000, pp. 104-111

Authors: Goudemand, J Peynet, J Chambost, H Negrier, C Briquel, ME Claeyssens, S Derlon-Borel, A Guerois, C Caron, C Scherrmann, JM Debray, M Bridey, F

Citation: J. Goudemand et al., A cross-over pharmacokinetic study of a double viral inactivated factor IXconcentrate (15 nm filtration and SD) compared to a SD factor IX concentrate, THROMB HAEM, 80(6), 1998, pp. 919-924